Oragenics (Oragenics) Retained Earnings : $-208.67 Mil (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Oragenics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Oragenics's retained earnings for the quarter that ended in Mar. 2024 was $-208.67 Mil.

Oragenics's quarterly retained earnings declined from Sep. 2023 ($-193.47 Mil) to Dec. 2023 ($-206.22 Mil) and declined from Dec. 2023 ($-206.22 Mil) to Mar. 2024 ($-208.67 Mil).

Oragenics's annual retained earnings declined from Dec. 2021 ($-171.27 Mil) to Dec. 2022 ($-185.56 Mil) and declined from Dec. 2022 ($-185.56 Mil) to Dec. 2023 ($-206.22 Mil).

Oragenics Retained Earnings Historical Data

The historical data trend for Oragenics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Retained Earnings Chart

Oragenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-127.35

-154.45

-171.27

-185.56

-206.22

Oragenics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-188.41	-191.46	-193.47	-206.22	-208.67

Oragenics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Oragenics (AMEX:OGEN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Oragenics (Oragenics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

0A64:UK

Address

4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634

Website

https://www.oragenics.com

Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.

Executives

Fred Telling	director	501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr.	director	C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman	officer: CFO, Secretary and Treasurer	5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski	director, 10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan	officer: CFO, Secretary and Treasurer	3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez	10 percent owner	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp	10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn	director, officer: CEO and President	39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope	director	4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski	director, 10 percent owner	1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski	10 percent owner
Thomas L Koski	10 percent owner